| PAI | plasminogen activator inhibitor |
| tPA | tissue-type plasminogen activator |
| uPA | urokinase-type plasminogen activator |
| ECM | extra cellular matrix |
| α2-PI | α2-plasmin inhibitor |
| α2-MG | α2-macroglobulin |
| RCL | reactive center loop |
| LMW | low molecular weight |
| HMW | high molecular weight |
| PCI | protein C inhibitor |
| uNK | uterine natural killer |
| EVT | extravillous cytotrophoblast |
| uPAR | uPA receptor |
| LRP | low density lipoprotein receptor-related protein |
| TIMP | tissue inhibitors of metalloprotease |
| TNF-α | tumor necrosis factor α |
| MMP | metalloproteinase |
| Jak/-Stat | Janus kinase 2/signal transducer and activator of transcription protein |
| NF-κB | nuclear factor κ-light-chain-enhancer of activated B cells |
| ACE | angiotensin I-converting enzyme |
| IL-1β | interleukin 1β |
| VEGF | vascular endothelial growth factor |
| EGF | epidermal growth factor |
| FGF | fibroblast growth factor |
| HIF | hypoxia-inducible transcription factors |
| p38 MAPK | p38 mitogen-activated protein kinases |
| PPAR-γ | peroxisome proliferator-activated receptor γ |
| RKIP | raf kinase inhibitor protein |
| ESR | estrogen receptor |
| PGR | progesterone receptor |
| SI | sensitivity index |
| BMI | body mass index |
| HOMA | homeostasis model assessment |
| CL | corpus luteum |
| RPL | recurrent pregnancy losses |
| IF | implantation failure |
| IUGR | intrauterine growth restriction |
| GDM | gestational diabetes mellitus |
| PCOS | polycystic ovary syndrome |
| MI | myocardial infarction |